Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.42Last Year’s EPS
-0.72Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: -31.73%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements like the FDA approval and commercial success of OJEMDA, coupled with strong financials and strategic partnerships. However, challenges include some product discontinuations and slower adoption in certain accounts. Overall, the positives outweigh the negatives, indicating strong company momentum.Company Guidance
During the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call, key metrics were highlighted showcasing the company's success and future plans. OJEMDA, their new pediatric low-grade glioma treatment, generated $57.2 million in net product revenues for 2024, with $29 million in the fourth quarter alone, marking a 44% increase from Q3. The company also improved its gross-to-net deductions, achieving a 12-15% forward-looking gross-to-net range after CMS granted an exclusively pediatric designation. The FIREFLY-2 trial, a Phase III study for tovorafenib, is underway with over 110 sites globally and aims for full enrollment by mid-2026. Additionally, Day One ended the year with over $500 million in cash, providing a strong financial base for continued investment in pipeline expansion and commercialization efforts.FDA Approval and Launch of OJEMDA
OJEMDA was approved by the FDA for relapsed/refractory pediatric low-grade glioma, marking a significant achievement for Day One Biopharmaceuticals and offering a new treatment option for patients.
Strong Revenue Growth
OJEMDA generated over $57 million in net product revenues in 2024, with fourth-quarter revenues reaching $29 million, representing a 44% growth compared to Q3.
Ex-U.S. Partnership with Ipsen
Day One established an exclusive licensing arrangement with Ipsen for ex-U.S. rights to OJEMDA, potentially expanding access to international markets.
Advancement of Clinical Trials
The FIREFLY-2 trial for tovorafenib is now open at over 110 sites globally, with full enrollment expected by the first half of 2026. The DAY301 program has also cleared the first dose cohort in its trial.
Strong Financial Position
Day One ended 2024 with over $500 million in cash, enabling continued investment in pipeline advancement without requiring external financing.
---
DAWN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DAWN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $11.82 | $9.87 | -16.50% |
| Oct 30, 2024 | $14.47 | $14.72 | +1.73% |
| Jul 30, 2024 | $15.36 | $15.19 | -1.11% |
| May 06, 2024 | $16.60 | $17.08 | +2.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Day One Biopharmaceuticals (DAWN) report earnings?
Day One Biopharmaceuticals (DAWN) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Day One Biopharmaceuticals (DAWN) earnings time?
Day One Biopharmaceuticals (DAWN) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DAWN EPS forecast?
DAWN EPS forecast for the fiscal quarter 2025 (Q1) is -0.42.
---